Pemphigoid diseases (PD) are a subgroup of rare acute or chronic autoimmune skin disorders characterized and caused by autoantibodies directed against distinct structural components of the dermal-epidermal junction. Binding of autoantibodies to their targets leads to the formation of blisters and erosions in patients. PDs comprise eight disorders for which the molecular target antigens have been identified. First, we review the available in vitro and ex vivo models for analysis of distinct aspects of the pathogenesis of PDs. This includes the binding of autoantibodies to skin sections, the analysis of blister formation capability and skin complement activation as well as investigation of neutrophil and keratinocyte activation. In addition to this, several animal models of PD have been developed during the last decades. These animal models have greatly contributed to our current understanding of the pathogenesis of PDs. We summarize spontaneously arising PD in animals and the induction of PD by transfer of (auto)antibodies, transfer of (auto)-antigen-specific lymphocytes and by immunization.
| INTRODUCTION
Pemphigoid diseases (PDs) are the most common autoimmune blistering skin disorders. They characterized and caused by autoantibodies directed against distinct structural components of the dermal-epidermal junction (DEJ) [1, 2] and share similarities with a number of other autoantibody-mediated diseases [3] (Figure 1 ). PDs commonly develop among the elderly. [2] Clinically, tense blister formation and itchy urticarial erythema are distinctive features of PDs. Histopathologically, subepidermal blister formation associated with eosinophilic and neutrophilic infiltration is characteristic of this condition. [2, 4] According to Schmidt et al, PDs can be categorized into two major subtypes, depending on the localization of the autoantibodies: first, bullous pemphigoid (BP) with autoantibodies against subepidermal structures and second, epidermolysis bullosa acquisita (EBA) with subepithelial autoantibodies. [2, 5] However, the classification of EBA as PD is controversial. The fact that the antigen (collagen VII, COL7 see Figure S2A )
is located subepithelial at the DEJ does support the fact that EBA is rather different from other PDs. Clinically, EBA is a heterogeneous disease that can either appear as mechanobullous classic form or Katja Bieber and Hiroshi Koga contributed equally.
an inflammatory variant. [2, 5] The inflammatory subtype can resemble other forms of PD clinically as well as histologically (bullous pemphigoid, BP, or mucous membrane pemphigoid, MMP), therefore use the term PD for the total of 8 diseases that are summarized in Table 1 .
Autoantibodies produced in BP target transmembrane Collagen XVII (COL17, also known as BP180, see Figure S1A ) and intracytoplasmic BP230; [2, 6] all these targets are vital molecules that maintain tight adhesion along DEJs. Another PD that includes COL17 as a target is mucous membrane pemphigoid (MMP), in which the following six targets are associated with the clinical phenotype: COL17 (in approximately 75% of patients), BP230 (25% reactivity), laminin 332 (25% reactivity), and both subunits of α6β4 integrin and COL7. Furthermore, pemphigoid gestations and lichen planus pemphigoid show antibodies against COL17 NC16A domain and/or BP230. In addition, few patients have a pemphigoid disease that is characterized by renal insufficiency and autoantibodies against the α5-chain of type IV collagen (α5(IV)COL). [7] In total, PD includes eight disorders, which are summarized in Table 1 . [2, 7] The investigation of PDs is important to improve our understanding of these life-threatening and difficult-to-treat diseases. For that reason, we use different in vivo and in vitro models for testing new therapeutics and for unravelling the pathomechanistic processes that finally induce blister formation. In this review, we focus on the in vivo models of PD and present detailed data about in vitro models as well as the according protocols in the Appendix (S1-S7).
Animal models are indispensable for investigating the pathogenesis of autoimmune diseases; these models include the transfer of autoantibodies to experimental animals, the adoptive transfer of autoantibodyproducing B cells to immune-deficient mice and the construction of transgenic mice that produce autoantibodies [8] (see Table 2 , Figure 2 ).
In PDs, experimental animal models established using several protocols are available [8] [9] [10] and have demonstrated the capacity for disease induction caused by autoantibodies to specific proteins (Tables 3-5 ).
Animal models are also useful for exploring the autoantibody-inducing interactions of molecules underlying the pathomechanism [11] and for choosing a therapeutic target candidate. [12, 13] Using animal models,
novel therapeutic interventions can be tested. [12, 14] Although animal models have many benefits, as described above, both the advantages
and disadvantages of each model should be considered.
| ANTIBODY TRANSFER-INDUCED MODELS

| Antibody transfer-induced models of BP
The passive transfer of IgG autoantibodies from patients with BP into animals has generally failed to reproduce blistering diseases. [15] This lack of an effect is most likely because the amino acid sequences of the most antigenic domain of hCOL17, the NC16A domain, differ from those of animals and due to the fact that passively transferred pemphigoid patient autoantibodies may not optimal interact with the host's innate factors. [16] In 1993, Lui et al reported that rabbit IgG antibodies targeting the juxtamembranous NC14A domain of mCOL17 (corresponding to the NC16A domain of hCOL17) are pathogenic ( Figure S1B ). When these antibodies are passively transferred into neonatal wild-type mice, they bind the DEJ, followed by complement activation, mast cell degradation and the recruitment of neutrophils; lastly, epidermal detachment via mild friction was induced. [17] This phenomenon was not reproducible in complement (C) 5 knockout mice, suggesting that complement activation is essential in this model although complement-independent blister formation is discussed. [18, 19] Using various transgenic mice as recipients, these authors reported that blistering disease in this experimental BP model is induced by anti-mCol17 IgG, which activates complement proteins following mast cell degradation, neutrophil infiltration and the degradation of mCol17. [20] [21] [22] [23] To avoid the use of neonatal mice, several adult BP models have been established using adult animals that can better reflect the fact that BP develops normally in elderly people. [24] [25] [26] In all models, a frequent injection of rabbit anti-mCOL17 either s.c. or i.p. leads to the formation of skin erosions, crust, erythema and hair loss. As mentioned above, it has been challenging to elucidate the pathogenic roles of human BP autoantibodies because of species' differences in the amino acid 
COL17
m-/-, h+ ) [27] or mCOL17 expressing human NC16A domain (partially COL17-humanized) [28] have been produced ( Figure S1B ).
When IgG autoantibodies from patients with BP were passively transferred into these animals, dermal-epidermal detachment was reproduced via mechanical friction. Thus, these models revealed the pathogenic roles of BP autoantibodies. Interestingly, the passive transfer of F(ab')2 rabbit antibodies or the mouse IgG1 monoclonal antibodies targeting the NC16A domain of hCOL17 might induce skin fragility in COL17-humanized neonatal mice. [29, 30] These antibodies have lower complement-activating ability, suggesting that a complement-independent mechanism is also involved in the patho- F I G U R E 2 Principles of animal models PD. Available antibody transfer models (left box): Injection of anti-COL17 or anti-COL7 in either neonatal or adult or humanized mice results in skin lesions over several days. Injection of anti-LAM332 in either adult mice resulted in oral and skin lesions over several days. SCID mice were human skin engrafted and injected with anti-hLAM332 or LADB95.
Immunization-induced models (right box): Immunization with recombinant mCOL7 or mCOL17 in Titermax™ led to the production of antibodies and typical signs of inflammatory EBA with crusts, alopecia, erythema and erosions. C57BL/6 mice were engrafted with skin from COL17 m-/-, h+ mice. The spleen cells of these mice (containing B cells that produce anti-hCOL17) were i. deplete cell surface hCOL17 after forming immune complexes. This process is mediated by the macrocytosis-dependent phosphorylation of hCOL17. [31] This in vitro finding was confirmed via the passive transfer of non-pathogenic mouse IgG1 monoclonal antibodies targeting the C-terminus of hCOL17 into COL17-humanized neonatal mice.
[32]
| Antibody transfer-induced models of EBA
Sitaru et al [33] established the first animal model for EBA by generating polyclonal rabbit antibodies to fragments of the immunodominant NC1 domain of mCOL7 [33] ( Figure S2B ). They transferred purified IgG antibodies from the sera of immunized rabbits. When mice were repeatedly injected with purified rabbit IgG at doses of 0.3-0.9 mg/g BW, subepidermal blisters and erosions developed after 2-4 days in a dose-dependent manner (for scoring procedure see Appendix S7).
In addition, various degrees of neutrophil infiltration and IgG/C3 deposits at the DEJ were found together with circulating anti-mCOL7
autoantibodies that were correlated with the extent of the disease.
Several inbred mouse strains were susceptible to blister induction via the injection of anti-mCOL7 antibodies in a differing disease range, [33, 34] which indicates a strong effect of genetic factors in the inflammatory processes. Additional work using an adult mouse model for EBA demonstrated that the alternative complement pathway, [35] neutrophils, CD18, NADPH oxidase, [36] GM-CSF, [37] IL-6, [38] TNF-α, [39] Hsp90, [40] CXCR1/2 [41] and the neonatal Fc-receptor [42] are crucial for the pathogenesis of experimental EBA. To avoid the non-specific effects of high levels of rabbit IgG, this model was refined using affinitypurified IgG. [10] In this case, the injection of 10 μg/g of body weight is sufficient to induce subepidermal blisters and erosions. Similarly, Woodley et al developed an antibody transfer model using IgG from rabbit antibodies to the NC1 domain of hCOL7. [43] Furthermore, affinity-purified IgG, but not F(ab) 2 fragments, from human EBA patients can induce clinical EBA lesions in SKH1 mice. [44] Two other groups developed similar approaches and successfully induced clinical EBA in mice. [45, 46] In a recently published study, [47] rabbit antibodies against recombinant proteins encompassing parts of the human NC1 domain of mCOL7 were produced and injected into COL7-humanized mice (these mice carry null mutations of mCOL7 and the hCOL7 transgene, COL7 m-/-, h+ ; Figure S2B ). These autoantibodies (anti-FNIII4-FNIII5 or anti-FNIII7-FNIII8) to hCOL7 induced blisters both ex vivo and in vivo.
| Antibody transfer-induced models of MMP
Mucous membrane pemphigoid (MMP) is a PD that predominantly affects the oral cavity, pharynx, and conjunctiva. Conjunctival lesions can lead to impaired vision and, ultimately, blindness. Approximately 25% of patients with MMP generate autoantibodies against the α3 chain of laminin 332 (LAMα3), a structural protein of epidermal/epithelial basement membranes. [48, 49] In the first animal models developed by Lazarova et al in 1996, hLAM322 was purified from the extracellular matrix of cultured human keratinocytes and used to immunize rabbits ( Figure S3B ). Neonatal or adult mice were injected with the resulting rabbit anti-hLAM332 IgG or F(ab) fragments and developed tense blisters on their abdomen, feet, and/or ears, often accompanied by faint, localized erythema. [50] [51] [52] The same group also established a humanized model using SCID mice bearing human skin grafts ( Figure   S3B ). Again, the injection of anti-hLAM332 IgG or patient IgG into the graft resulted in epidermal fragility and non-inflammatory, subepidermal blisters. These models lack severe oral and pharyngeal le- Heppe et al [53] will hopefully help to dissect the pathophysiology of MMP and explore the effect of more specific anti-inflammatory mediators on mucosal and skin lesions.
| Antibody transfer-induced models of linear IgA bullous dermatoses (LADs)
IgA is present in the skin of several PDs; however, the hallmark of IgA autoimmune disorders of the skin is the deposition of IgA in tissue at the site of the inflammatory process. In these disorders, IgA is the predominant immunoglobulin detected in the skin. Next, infiltration of neutrophils into the skin occurs, and the function of structural proteins is compromised. This effect produces a vesiculation or blood vessel destruction that is clinically evident as vesicles, bullae and purpura. Dapsone usually inhibits the inflammatory process, but it does not inhibit the deposition of IgA in the skin. [2, 54] Although COL17 is the major antigen in LABD in humans, the primary site of antigenic reactivity for BP (MCW1) differs from that for linear
IgA bullous dermatosis and is directed against the double-truncated ectodomain of hCOL17. [54] Therefore, Zone et al developed two monoclonal mouse IgA antibodies that were directed against human LABD97 and injected the antibody into transplanted human neonatal foreskin grafts in athymic or SCID mice. The administration of IgA antibodies led to neutrophil infiltration and basement membrane vesiculation in 4 of the 12 mice tested. [54] The development of a mouse LAD model is not possible due to the fact that mice do not express the IgA receptor (CD89) [55] but several other receptors are described that bind IgA in mice like the polymeric immunoglobulin receptor (IgR), asialoglycoprotein receptor (ASGP-R) and transferrin receptor (TfR). [56] Due to the fact that these receptors cannot overtake the whole function of the IgA receptor, we need humanized models for the study of LADs.
| Advantages and disadvantages of autoantibody transfer
The use of antibody transfer models more closely resembles the clinical situation than the use of ex vivo models and enables the examination of the effector phase of EBA. Testing therapeutic drugs or investigating the pathogenesis of EBA is easily performed because the clinical symptoms are visible days after the IgG transfer. However, similar to most animal models, the situation in human patients is not reflected because the signalling cascade and the interaction of different cell types vary between humans and mice. In addition, induced disease might last less than a few days after the transfer of antibodies.
Furthermore, the processes that lead to the loss of tolerance and the production of autoreactive antibodies cannot be studied using these models.
| IMMUNIZATION-INDUCED DISEASE MODELS
| Immunization-induced models of BP
BP is a chronic disease that is usually observed in elderly adults;
in addition, circulating autoantibodies targeting hCOL17 are persistently observed. [2] By contrast, circulating autoantibodies targeting mCOL17 are not persistently present in antibody transfer-induced BP models, and neonatal mice are commonly used. Thus, adult BP models with similar characteristics of humans with BP are required.
A previous study showed that the immunization of female SJL/J mice via mouse NC14A domain polypeptides (which correspond to the NC16A domain of hCOL17) can break the tolerance to mCOL17 in immunized mice, thereby showing similar immunopathological features with those of BP [57] ( Figure S1C ). However, only 56% of female mice in this model were diseased and none of the males, which indicates that breaking the tolerance to mCOL17 is challenging. As an alternative model, Ujiie et al reported that the transfer of spleen cells from wild-type mice that had been skin-grafted from hCOL17-expressing transgenic mice skin into the immune compromised Rag2-/-COL17-humanized mice induces similar phenotypes to those of BP [58] ( Figure S1C ). This active BP model was produced based on a previous study showing that the grafting of skin from hCOL17-expressing transgenic mice onto syngeneic wild-type mice induces potential immune reactions against hCOL17 in recipient mice. [59] By selectively transferring T-cell subtypes, CD4+ T cells but not CD8+ T cells play essential roles in the pathogenesis of the active adult BP model. [58] 
| Immunization-induced models of EBA
In 2006, an immunization-induced disease model for EBA was established [60] ( Figure S2C ). In this model, mice were immunized with a recombinant peptide fragment from the immunogenic NC-1 domain of mCOL7 to produce a GST fusion protein. [61] Th1 polarization [62] and the formation of complement-binding autoantibodies of the IgG2a and IgG2b subclasses. [60] Subsequently, a dependency on T cells was identified, as evidenced by mice lacking T cells (SJL nu/nu mice) that were resistant to disease induction. Moreover, the adoptive transfer of immunity to mCOL7 from immune-competent SJL mice into SJL nu/nu mice led to EBA in recipient mice. [63] Subsequently, Iwata et al [64] developed a second immunization model using a single immunization with 60 μg mCOL7 in Titermax™ (Sigma-Aldrich, St. Luis, Missouri, USA). In that model, the immunodominant murine von
Willebrand factor A2-like domain (vWFA2) of the NC1 domain [65] was used to immunize mice. Again, the disease was linked to the H2S haplotype and required APC-induced CD4 T cells, dendritic cells and macrophages. [64, 66] 
| Advantages and disadvantages of immunization-induced disease models
Immunization-induced disease models are suitable for the investigation of all aspects of autoimmune skin blistering diseases, including long-term therapeutic intervention. They enable not only the investigation of the mechanisms leading to a loss of tolerance but also the evaluation of long-term therapeutic effects. However, although the models duplicate the clinical, histopathological, ultrastructural and immunological features of the human disease, these systems are mostly completely murine, and it is possible that findings in mice will not translate to humans. In addition, the effects of adjuvants during immunization remain largely unknown. One exception is the use of the model developed by Ujijie et al, [58] who humanized the presence of COL17 and avoided the use of adjuvants. However, the subsequent inflammatory processes and the antibody-producing cells are of murine origin. loss. These models are normally challenging because the natural tolerance against the proteins of skin components must be overwhelmed. The fact that adjuvants are needed does not completely reflect the human situation, but here, drugs against the acquired immune response can be tested and the early phases of the disease progression can be studied. However, besides the intense use of the here described model systems for PDs, many questions remain to be investigated in the future and many new therapeutic strategies have to be evaluated.
| CONCLUSION
